These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 26623513)

  • 1. The 3-I framework: a framework for developing public policies regarding pharmacogenomics (PGx) testing in Canada.
    Bashir NS; Ungar WJ
    Genome; 2015 Dec; 58(12):527-40. PubMed ID: 26623513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addressing ethical challenges at the intersection of pharmacogenomics and primary care using deliberative consultations.
    Longo C; Rahimzadeh V; O'Doherty K; Bartlett G
    Pharmacogenomics; 2016 Nov; 17(16):1795-1805. PubMed ID: 27767407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public perceptions of pharmacogenetics.
    Zhang SC; Bruce C; Hayden M; Rieder MJ
    Pediatrics; 2014 May; 133(5):e1258-67. PubMed ID: 24777223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What Do Students in Pharmacy and Medicine Think About Pharmacogenomics and Personalized Medicine Education? Awareness, Attitudes, and Perceptions in Malaysian Health Sciences.
    Siamoglou S; Koromina M; Moy FM; Mitropoulou C; Patrinos GP; Vasileiou K
    OMICS; 2021 Jan; 25(1):52-59. PubMed ID: 33170085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Informed consent in the context of pharmacogenomic research: ethical considerations.
    Howard HC; Joly Y; Avard D; Laplante N; Phillips M; Tardif JC
    Pharmacogenomics J; 2011 Jun; 11(3):155-61. PubMed ID: 21445091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications.
    Garrison LP; Carlson RJ; Carlson JJ; Kuszler PC; Meckley LM; Veenstra DL
    Drug Metab Rev; 2008; 40(2):377-401. PubMed ID: 18464050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors influencing uptake of pharmacogenetic testing in a diverse patient population.
    O'Daniel J; Lucas J; Deverka P; Ermentrout D; Silvey G; Lobach DF; Haga SB
    Public Health Genomics; 2010; 13(1):48-54. PubMed ID: 19407441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Collaborative Counseling Considerations for Pharmacogenomic Tests.
    Zierhut HA; Campbell CA; Mitchell AG; Lemke AA; Mills R; Bishop JR
    Pharmacotherapy; 2017 Sep; 37(9):990-999. PubMed ID: 28672074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of a pharmacist-led pharmacogenomics service for the Program of All-Inclusive Care for the Elderly (PHARM-GENOME-PACE).
    Bain KT; Schwartz EJ; Knowlton OV; Knowlton CH; Turgeon J
    J Am Pharm Assoc (2003); 2018; 58(3):281-289.e1. PubMed ID: 29602745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary care physician experiences with integrated pharmacogenomic testing in a community health system.
    Lemke AA; Hutten Selkirk CG; Glaser NS; Sereika AW; Wake DT; Hulick PJ; Dunnenberger HM
    Per Med; 2017 Sep; 14(5):389-400. PubMed ID: 29754567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug Administration.
    Phillips KA; Van Bebber SL
    Med Care Res Rev; 2006 Jun; 63(3):301-26. PubMed ID: 16651395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ethics, politics, and rights in pharmacogenomics].
    Bellver Capella V
    Rev Derecho Genoma Hum; 2002; (17):31-55. PubMed ID: 12703107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics, ethics, and public policy.
    Peterson-Iyer K
    Kennedy Inst Ethics J; 2008 Mar; 18(1):35-56. PubMed ID: 18561577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the readiness of physicians for pharmacogenomics testing: an empirical assessment.
    Amara N; Blouin-Bougie J; Bouthillier D; Simard J
    Pharmacogenomics J; 2018 Apr; 18(2):308-318. PubMed ID: 28607504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knowledge, attitude, and practice towards pharmacogenomics among hospital pharmacists in Thailand.
    Karuna N; Tragulpiankit P; Mahasirimongkol S; Chumnumwat S
    Pharmacogenet Genomics; 2020 Jun; 30(4):73-80. PubMed ID: 32187156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of a personal CYP2D6 testing workshop on physician assistant student attitudes toward pharmacogenetics.
    O'Brien TJ; LeLacheur S; Ward C; Lee NH; Callier S; Harralson AF
    Pharmacogenomics; 2016 Mar; 17(4):341-52. PubMed ID: 26907849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient perspectives following pharmacogenomics results disclosure in an integrated health system.
    Lemke AA; Hulick PJ; Wake DT; Wang C; Sereika AW; Yu KD; Glaser NS; Dunnenberger HM
    Pharmacogenomics; 2018 Mar; 19(4):321-331. PubMed ID: 29469671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacogenomics testing in the era of next generation sequencing: challenges and opportunities for precision medicine.
    Ji Y; Si Y; McMillin GA; Lyon E
    Expert Rev Mol Diagn; 2018 May; 18(5):411-421. PubMed ID: 29634383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of Pharmacogenomics in Everyday Clinical Settings.
    Bank PCD; Swen JJ; Guchelaar HJ
    Adv Pharmacol; 2018; 83():219-246. PubMed ID: 29801576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.